Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study

Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, JapanCorrespondence[email protected]

Kazuhiko YamamotoDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

Hisashi YamanakaInstitute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan

Naoki IshiguroDepartment of Orthopedic Surgery, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Aichi, Japan

Katsumi EguchiSasebo City General Hospital, Sasebo, Nagasaki, Japan

Akira WatanabeResearch Division for Development of Anti-Infectious Agents, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan

Hideki OrigasaDivision of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan

Toshiharu ShojiDepartment of Clinical Research and Development, UCB, Shinjuku-ku, Tokyo, Japan

Nobuyuki MiyasakaDepartment of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan

Takao KoikeNTT Sapporo Medical Center, Sapporo, Hokkaido, Japan

show all

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date